We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Allakos Inc | NASDAQ:ALLK | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.02 | 1.90% | 1.07 | 1.06 | 1.17 | 1.18 | 1.05 | 1.06 | 428,288 | 23:20:40 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 21, 2021 |
Allakos Inc.
(Exact name of Registrant as Specified in Its Charter)
Delaware |
001-38582 |
45-4798831 |
||
(State or Other Jurisdiction
|
(Commission File Number) |
(IRS Employer
|
||
|
|
|
|
|
975 Island Drive, Suite 201 |
|
|||
Redwood City, California |
|
94065 |
||
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s Telephone Number, Including Area Code: 650 597-5002 |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading
|
|
|
Common Stock, par value $0.001 |
|
ALLK |
|
The Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
Release of Study Results
On December 21, 2021, Allakos Inc. (the “Company”) issued a press release announcing its topline Phase 3 data from the ENIGMA 2 study of lirentelimab in patients with eosinophilic gastritis and/or eosinophilic duodenitis and Phase 2/3 data from the KRYPTOS study of lirentelimab in patients with eosinophilic esophagitis met histologic co-primary endpoints, but did not achieve statistical significance on the patient reported symptomatic co-primary endpoints. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit |
|
Description |
|
|
|
99.1 |
|
|
|
|
|
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
Allakos Inc. |
|
|
|
|
Date: |
December 21, 2021 |
By: |
/s/ H. Baird Radford, III |
|
|
|
H. Baird Radford, III
|
1 Year Allakos Chart |
1 Month Allakos Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions